Advanced search
1 file | 261.00 KB
Author
Organization
Abstract
Background: Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. Objective: We sought to provide a targeted update of the ARIA guidelines. Methods: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. Results: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H-1-antihistamines, intranasal H-1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. Conclusions: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.
Keywords
Allergic rhinitis, practice guideline, EUROPEAN INNOVATION PARTNERSHIP, INDEPENDENT RISK-FACTOR, RESPIRATORY-DISEASE, PERENNIAL RHINITIS, AIRWAYS-ICPS, IMPLEMENTATION, HEALTH, PREVALENCE, GA(2)LEN, BURDEN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 261.00 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Brożek, Jan L, Jean Bousquet, Ioana Agache, Arnav Agarwal, Claus Bachert, Sinthia Bosnic-Anticevich, Romina Brignardello-Petersen, et al. 2017. “Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines : 2016 Revision.” Journal of Allergy and Clinical Immunology 140 (4): 950–958.
APA
Brożek, J. L., Bousquet, J., Agache, I., Agarwal, A., Bachert, C., Bosnic-Anticevich, S., Brignardello-Petersen, R., et al. (2017). Allergic rhinitis and its impact on asthma (ARIA) guidelines : 2016 revision. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 140(4), 950–958.
Vancouver
1.
Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines : 2016 revision. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2017;140(4):950–8.
MLA
Brożek, Jan L, Jean Bousquet, Ioana Agache, et al. “Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines : 2016 Revision.” JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY 140.4 (2017): 950–958. Print.
@article{8538875,
  abstract     = {Background: Allergic rhinitis (AR) affects 10\% to 40\% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. 
Objective: We sought to provide a targeted update of the ARIA guidelines. 
Methods: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. 
Results: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H-1-antihistamines, intranasal H-1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. 
Conclusions: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.},
  author       = {Bro\.{z}ek, Jan L and Bousquet, Jean and Agache, Ioana and Agarwal, Arnav and Bachert, Claus and Bosnic-Anticevich, Sinthia and Brignardello-Petersen, Romina and Canonica, G Walter and Casale, Thomas and Chavannes, Niels H and Correia de Sousa, Jaime and Cruz, Alvaro A and Cuello-Garcia, Carlos A and Demoly, Pascal and Dykewicz, Mark and Etxeandia-Ikobaltzeta, Itziar and Florez, Ivan D and Fokkens, Wytske and Fonseca, Joao and Hellings, Peter W and Klimek, Ludger and Kowalski, Sergio and Kuna, Piotr and Laisaar, Kaja-Triin and Larenas-Linnemann, D{\'e}sir{\'e}e E and L{\o}drup Carlsen, Karin C and Manning, Peter J and Meltzer, Eli and Mullol, Joaquim and Muraro, Antonella and O'Hehir, Robyn and Ohta, Ken and Panzner, Petr and Papadopoulos, Nikolaos and Park, Hae-Sim and Passalacqua, Gianni and Pawankar, Ruby and Price, David and Riva, John J and Rold{\'a}n, Yetiani and Ryan, Dermot and Sadeghirad, Behnam and Samolinski, Boleslaw and Schmid-Grendelmeier, Peter and Sheikh, Aziz and Togias, Alkis and Valero, Antonio and Valiulis, Arunas and Valovirta, Erkka and Ventresca, Matthew and Wallace, Dana and Waserman, Susan and Wickman, Magnus and Wiercioch, Wojtek and Yepes-Nu{\~n}ez, Juan Jos{\'e} and Zhang, Luo and Zhang, Yuan and Zidarn, Mihaela and Zuberbier, Torsten and Sch{\"u}nemann, Holger J},
  issn         = {0091-6749},
  journal      = {JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY},
  language     = {eng},
  number       = {4},
  pages        = {950--958},
  title        = {Allergic rhinitis and its impact on asthma (ARIA) guidelines : 2016 revision},
  url          = {http://dx.doi.org/10.1016/j.jaci.2017.03.050},
  volume       = {140},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: